Skip to main content

Table 1 Baseline clinical characteristics of HCV-infected patients included in the present study

From: Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C

Characteristics

SVR

NR

P value

Statistics (univariate)

(n = 91

(n = 109)

OR(95%CI)

Age mean ± SD (years)

49.7 ± 7.5

51.5 ± 8.5

-

 

Gender distribution[n(%)]

  

-

 

 Male

61(67)

68(62.4)

  

 Female

30(33)

41(37.6)

  

BMI, median (range), kg/m2

23 ± 12

24 ± 13.5

-

 

No of injections, median (range)

48(24)

48(67)

0.001

1.035(1.013-1.058)

Tolerability, [n(%)]

91(100)

88(80.7)

-

*Adjusted No of injections ,mean ± SEM

39.23 ± 1.179

38.218 ± 1.072

-

 

Viral load median, IU/mL

460,000

760,580

0.025

0.637(0.429-0.945)

400,000 IU/mL[n(%)] > Viral load

41(45.1)

38(34.9)

-

 

Viral load ≥400,000 IU/mL[n(%)]

50(54.9)

71(65.1)

-

 

aAST median (range), μkat/L

1.66(4.65)

1.44(4.22)

-

 

bALT median (range), μkat/L

2.04(6.22)

1.7(5.63)

-

 

Albumin median (range), g/L

39 ± 20

39 ± 22

-

 

Bilirubin median (range), μmol/L

13.68 ± 50.45

15.39 ± 44.46

-

 

Hemoglobin median (range), g/dL

13 ± 6.1

13.5 ± 7

-

 

Platelets median (range), 109/L

190(241)

160(320)

0.012

3.299(1.306-8.334)

cTLC median (range), 109/μL

6(10)

6.4(6)

-

 

Cholesterol mean ± SD, mmol/L

4.41 ± 0.78

4.69 ± 0.66

-

 

Glucose median (range), mmol/L

5.27 ± 3.38

5.5 ± 3.1

-

 

Insulin median (range), pmol/L

79.8 ± 127

62.5 ± 147.2

-

 

dHOMA-IR median (range)

2.4 ± 5.71

2.2 ± 6.8

-

 

eAFP median (range), ng/mL

3.3(29.5)

7(29)

<0.001

0.165(0.071-0.383)

25-OH Vitamin D median (range),ng/mL

28 ± 38

19 ± 38

<0.001

4.877(2.512-9.468)

Cirrhosis, [n(%)]

5(5.5)

15(13.7)

-

 

Fibrosis stage, [n(%)]

    

 F1

21(42)

12(18.4)

0.006

3.198(1.378-7.419)

 F2

16(32)

29(44.6)

-

 

 F3

12(24)

16(24.6)

-

 

 F4

1(2)

8(12.3)

-

 

Necroinflammatory grade, [n(%)]

    

 A1

26(52)

27(41.5)

-

 

 A2

22(44)

27(41.5)

-

 

 A3

2(4)

11(17)

0.04

0.204(0.043-0.97)

IL28B rs12979860 [n(%)]

  

Chi2 = 55.2 p < 0.001

 C/C

56(61.5)

14(12.8)

<0.001

10.857(5.379-21.913)

 C/T

31(34.1)

67(61.5)

<0.001

0.324(0.181-0.579)

 T/T

4(4.4)

28(25.7)

<0.001

0.133(0.045-0.395)

T allele carriers/ T allele non carriers

35/56

94/14

<0.001

0.092(0.046-0.186)

  1. a AST, aspartate aminotransferase; b ALT, alanine aminotransferase; c TLC, total leukocyte count; d HOMA-IR, homeostatic model of insulin resistance; e AFP, alfa feto protein; NR, non-responders; SVR, sustained virological responders; N, number of samples; OR, odds ratio; 95%CI Confidence Interval.; Chi-square test for genotype distribution; IL28B: interleukin 28 B
  2. *Calculated by general linear model with adjustment for tolerability